Please assess the completion status of the following clinical trial:

Trial Title: Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients between 18 and 75 years;~2. Symptomatic subchondral bone marrow lesions of femoral condyles (grade ≥ 1 according to the WORMS MRI score);~3. Failure after at least two months of a conservative treatment;~4. Single BME areas involving a single compartment of the knee;~5. Availability of the patients to participate actively in the rehabilitation protocol and follow-up clinic and radiology;~6. Signature of informed consent.~Exclusion Criteria:~1. Patients incapable of discernment;~2. History of allergy to calcium phosphates;~3. Patients with malignancies;~4. Patients with rheumatic diseases;~5. Patients with diabetes;~6. Patients suffering of metabolic disorders of the thyroid;~7. Patients with history of abuse of alcohol, drugs or medication;~8. Patients with advanced osteoarthritis (Kellgren-Lawrence grade\> 3);~9. Body Mass Index\> 35;~10. BME that involve more than one compartment;~11. Patients with trauma in the 6 months prior to the intervention. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- core decompression technique (Type: ACTIVE_COMPARATOR): The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
- bone substitution (i-FactorTM) (Type: EXPERIMENTAL): i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
- injections of autologous Bone Marrow Concentrate (BMC) (Type: EXPERIMENTAL): injections of autologous BMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).